Kymera Therapeutics, Inc. - Common Stock (KYMR)
44.26
+0.68 (1.56%)
NASDAQ · Last Trade: Jun 5th, 12:23 AM EDT
Detailed Quote
Previous Close | 43.58 |
---|---|
Open | 43.73 |
Bid | 44.35 |
Ask | 45.50 |
Day's Range | 42.83 - 45.45 |
52 Week Range | 19.45 - 53.27 |
Volume | 1,144,672 |
Market Cap | 2.45B |
PE Ratio (TTM) | -14.85 |
EPS (TTM) | -3.0 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 573,310 |
Chart
About Kymera Therapeutics, Inc. - Common Stock (KYMR)
Kymera Therapeutics Inc is a biotechnology company focused on developing innovative therapeutics that harness the power of targeted protein degradation to treat a range of diseases, including cancer and autoimmune disorders. By utilizing its proprietary technology platform, the company aims to design and create small molecules that can selectively degrade specific proteins, thereby offering a novel approach to addressing previously difficult-to-target biological pathways. Kymera's pipeline includes a variety of drug candidates that advance the understanding of protein function and the potential for transformative treatments, positioning the company at the forefront of the next generation of precision medicine. Read More
News & Press Releases

Via Benzinga · June 3, 2025

Via Benzinga · June 3, 2025

Via Benzinga · June 3, 2025

Morgan Stanley, BofA, and Citi upgraded the stock, citing strong safety, biomarker, and degradation data for its STAT6 degrader KT-621.
Via Stocktwits · June 2, 2025

Via Benzinga · February 28, 2025

Wondering how the US markets performed one hour before the close of the markets on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · June 2, 2025

Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · June 2, 2025

Via Benzinga · June 2, 2025

Via Benzinga · October 30, 2024

Via Benzinga · September 9, 2024

Kymera's KT-621 achieved rapid, deep STAT6 degradation and showed a strong safety profile in Phase 1, with the next trials planned through early 2026.
Via Benzinga · June 2, 2025

Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · June 2, 2025

Via Benzinga · May 30, 2025

After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · May 30, 2025
Via Benzinga · May 12, 2025
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics.
Via Benzinga · April 27, 2025

Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via Benzinga · October 30, 2024